Sulfone Electrophiles in Cross-Electrophile Coupling: Nickel-Catalyzed Difluoromethylation of Aryl Bromides

Daniel Weix,Sebastien Monfette,Benjamin Chi,Benjamin Ahern,Samantha Gavin,Nikita Peperni
DOI: https://doi.org/10.26434/chemrxiv-2023-rpbs4-v2
2024-06-03
Abstract:Fluoroalkyl fragments have played a critical role in the design of pharmaceutical and agrochemical molecules in recent years due to the enhanced biological properties of fluorinated molecules compared to their non-fluorinated analogues. Despite the potential advantages conferred by incorporating a difluoromethyl group in organic compounds, industrial adoption of difluoromethylation methods lags be-hind fluorination and trifluoromethylation. This is due in part to challenges in applying common difluoromethyl sources towards indus-trial applications. We report here the nickel-catalyzed cross-electrophile coupling of (hetero)aryl bromides with difluoromethyl 2-pyridyl sulfone, a sustainably sourced, crystalline difluoromethylation reagent. The scope of this reaction is demonstrated with 24 examples (67 ± 16% average yield) including a diverse array of heteroaryl bromides and precursors to difluoromethyl-containing preclinical pharmaceuti-cals. This reaction can be applied to small-scale parallel synthesis and benchtop scale-up under mild conditions. As sulfone reagents are uncommon electrophiles in cross-electrophile coupling, the mechanism of this process was investigated. Studies confirmed the formation of •CF2H instead of difluorocarbene. A series of modified difluoromethyl sulfones revealed that sulfone reactivity does not correlate ex-clusively with reduction potential and that coordination of cations or nickel to the pyridyl group is essential to reactivity, setting out pa-rameters for matching the reactivity of sulfones in cross-electrophile coupling.
Chemistry
What problem does this paper attempt to address?
The paper attempts to address the issue of introducing difluoromethyl (CF2H) into organic compounds. Although fluorine-containing molecules exhibit enhanced biological properties in the design of pharmaceuticals and agrochemicals, methods for introducing difluoromethyl into organic compounds still face challenges in industrial applications. Specifically, existing difluoromethylation methods have the following issues: 1. **Limited functional group tolerance**: Some commonly used methods have poor tolerance to functional groups, limiting their application in complex molecules. 2. **Safety concerns**: Certain difluoromethylation reagents (such as DAST and its derivatives) pose safety hazards and are difficult to control in parallel synthesis and large-scale preparation. 3. **Environmental issues**: Many existing difluoromethylation methods rely on halomethane gases that deplete the ozone layer, which are strictly regulated or banned under the Montreal Protocol. 4. **Reagent stability**: Some difluoromethylation reagents are unstable, making them difficult to store and transport. To overcome these issues, the paper develops a new nickel-catalyzed cross-electrophile coupling reaction using difluoromethyl-2-pyridyl sulfone (2-PySO2CF2H) as the difluoromethylation reagent, coupling it with aryl bromides. This method has the following advantages: - **High reactivity and selectivity**: Efficiently generates difluoromethylated products under mild conditions. - **Broad substrate applicability**: Suitable for a variety of aryl and heteroaryl bromides, including substrates with different functional groups. - **Industrial applicability**: The reagents used are stable, readily available, and suitable for small-scale parallel screening and large-scale production. - **Mechanistic study**: Experimental validation of the reaction mechanism revealed that the sulfone structure significantly affects the reaction activity, particularly the coordination ability of the 2-pyridyl nitrogen atom, which is crucial for the reaction activity. In summary, the paper aims to develop a simple, practical, and selective difluoromethylation method to facilitate the discovery and manufacture of more potential drug candidates.